These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23187803)

  • 1. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.
    Leontieva OV; Lenzo F; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2012 Dec; 11(24):4642-9. PubMed ID: 23187803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK drives cyclin D1 hyperelevation during geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Differ; 2013 Sep; 20(9):1241-9. PubMed ID: 23852369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia suppresses conversion from proliferative arrest to cellular senescence.
    Leontieva OV; Natarajan V; Demidenko ZN; Burdelya LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2012 Aug; 109(33):13314-8. PubMed ID: 22847439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
    Stein GH; Drullinger LF; Soulard A; Dulić V
    Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth stimulation leads to cellular senescence when the cell cycle is blocked.
    Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2008 Nov; 7(21):3355-61. PubMed ID: 18948731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin, proliferation and geroconversion to senescence.
    Blagosklonny MV
    Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapamycin decelerates cellular senescence.
    Demidenko ZN; Zubova SG; Bukreeva EI; Pospelov VA; Pospelova TV; Blagosklonny MV
    Cell Cycle; 2009 Jun; 8(12):1888-95. PubMed ID: 19471117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate.
    Romanov VS; Abramova MV; Svetlikova SB; Bykova TV; Zubova SG; Aksenov ND; Fornace AJ; Pospelova TV; Pospelov VA
    Cell Cycle; 2010 Oct; 9(19):3945-55. PubMed ID: 20935470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.
    Shen H; Maki CG
    J Biol Chem; 2010 Jul; 285(30):23105-14. PubMed ID: 20489208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.
    Leontieva OV; Blagosklonny MV
    Oncotarget; 2014 Dec; 5(24):12715-27. PubMed ID: 25587030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
    Blagosklonny MV
    Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin.
    Leontieva OV; Demidenko ZN; Gudkov AV; Blagosklonny MV
    PLoS One; 2011; 6(10):e26126. PubMed ID: 22022534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S6K in geroconversion.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Cycle; 2013 Oct; 12(20):3249-52. PubMed ID: 24036549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism.
    Wang R; Yu Z; Sunchu B; Shoaf J; Dang I; Zhao S; Caples K; Bradley L; Beaver LM; Ho E; Löhr CV; Perez VI
    Aging Cell; 2017 Jun; 16(3):564-574. PubMed ID: 28371119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors.
    Blagosklonny MV
    Cell Cycle; 2011 Jul; 10(14):2295-8. PubMed ID: 21715978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical suppression of cellular senescence by p53.
    Demidenko ZN; Korotchkina LG; Gudkov AV; Blagosklonny MV
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9660-4. PubMed ID: 20457898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
    Huang S; Liu LN; Hosoi H; Dilling MB; Shikata T; Houghton PJ
    Cancer Res; 2001 Apr; 61(8):3373-81. PubMed ID: 11309295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.